Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism
The burden of obesity and associated cardiometabolic diseases has been considered as an important risk factor for lupus patients. Therefore, whether obesity is involved in the over-activation of autoimmune response has attracted more and more attention. Hydroxychloroquine is a synthetic antimalarial...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00855/full |
id |
doaj-ecd4b2c26a074a6aa419d96e50f04edf |
---|---|
record_format |
Article |
spelling |
doaj-ecd4b2c26a074a6aa419d96e50f04edf2020-11-25T01:15:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-08-011010.3389/fphar.2019.00855463660Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid MetabolismXin Qiao0Zhuo-Chao Zhou1Rui Niu2Yu-Tong Su3Yue Sun4Hong-Lei Liu5Jia-Lin Teng6Jun-Na Ye7Hui Shi8Cheng-De Yang9Xiao-Bing Cheng10Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaShanghai Pharmaceutical Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaThe burden of obesity and associated cardiometabolic diseases has been considered as an important risk factor for lupus patients. Therefore, whether obesity is involved in the over-activation of autoimmune response has attracted more and more attention. Hydroxychloroquine is a synthetic antimalarial drug and has been the clinical treatment of rheumatic diseases irreplaceable first-line drugs. Hydroxychloroquine has been suggested to have beneficial effects on lipids and insulin sensitivity, which may contribute in lowering high cardiovascular risk in SLE patients. However, its mechanism on insulin sensitivity and lipid disorders is far from being completely understood. In the present study, the therapeutic effects of hydroxychloroquine were evaluated under pathological conditions in vivo. Obesity was induced in C57BL/6 mice fed with high-fed diet, or in mice fed with high-fat diet and hydroxychloroquine. In addition, healthy mice that received normal chow diet were also monitored. The present results revealed that hydroxychloroquine reduced weight, hepatic steatosis, glucose, and insulin resistance. Furthermore, hydroxychloroquine downregulated the expression of peroxisome proliferator-activated receptor gamma in the liver. According to these present results, genes about lipid metabolism went down in high-fat mice liver. Hydroxychloroquine shows potential in ameliorating obesity-induced pathology, which acts though PPARγ to facilitate the healthy function of hepatic tissues. This evidence shows that hydroxychloroquine plays a role in improving obesity-induced lipotoxicity and insulin resistance though the peroxisome proliferator-activated receptor gamma pathway.https://www.frontiersin.org/article/10.3389/fphar.2019.00855/fullhydroxychloroquinehepatic steatosisdyslipidemiainsulin resistanceperoxisome proliferator-activated receptor gamma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xin Qiao Zhuo-Chao Zhou Rui Niu Yu-Tong Su Yue Sun Hong-Lei Liu Jia-Lin Teng Jun-Na Ye Hui Shi Cheng-De Yang Xiao-Bing Cheng |
spellingShingle |
Xin Qiao Zhuo-Chao Zhou Rui Niu Yu-Tong Su Yue Sun Hong-Lei Liu Jia-Lin Teng Jun-Na Ye Hui Shi Cheng-De Yang Xiao-Bing Cheng Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism Frontiers in Pharmacology hydroxychloroquine hepatic steatosis dyslipidemia insulin resistance peroxisome proliferator-activated receptor gamma |
author_facet |
Xin Qiao Zhuo-Chao Zhou Rui Niu Yu-Tong Su Yue Sun Hong-Lei Liu Jia-Lin Teng Jun-Na Ye Hui Shi Cheng-De Yang Xiao-Bing Cheng |
author_sort |
Xin Qiao |
title |
Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism |
title_short |
Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism |
title_full |
Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism |
title_fullStr |
Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism |
title_full_unstemmed |
Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism |
title_sort |
hydroxychloroquine improves obesity-associated insulin resistance and hepatic steatosis by regulating lipid metabolism |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2019-08-01 |
description |
The burden of obesity and associated cardiometabolic diseases has been considered as an important risk factor for lupus patients. Therefore, whether obesity is involved in the over-activation of autoimmune response has attracted more and more attention. Hydroxychloroquine is a synthetic antimalarial drug and has been the clinical treatment of rheumatic diseases irreplaceable first-line drugs. Hydroxychloroquine has been suggested to have beneficial effects on lipids and insulin sensitivity, which may contribute in lowering high cardiovascular risk in SLE patients. However, its mechanism on insulin sensitivity and lipid disorders is far from being completely understood. In the present study, the therapeutic effects of hydroxychloroquine were evaluated under pathological conditions in vivo. Obesity was induced in C57BL/6 mice fed with high-fed diet, or in mice fed with high-fat diet and hydroxychloroquine. In addition, healthy mice that received normal chow diet were also monitored. The present results revealed that hydroxychloroquine reduced weight, hepatic steatosis, glucose, and insulin resistance. Furthermore, hydroxychloroquine downregulated the expression of peroxisome proliferator-activated receptor gamma in the liver. According to these present results, genes about lipid metabolism went down in high-fat mice liver. Hydroxychloroquine shows potential in ameliorating obesity-induced pathology, which acts though PPARγ to facilitate the healthy function of hepatic tissues. This evidence shows that hydroxychloroquine plays a role in improving obesity-induced lipotoxicity and insulin resistance though the peroxisome proliferator-activated receptor gamma pathway. |
topic |
hydroxychloroquine hepatic steatosis dyslipidemia insulin resistance peroxisome proliferator-activated receptor gamma |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.00855/full |
work_keys_str_mv |
AT xinqiao hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT zhuochaozhou hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT ruiniu hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT yutongsu hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT yuesun hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT hongleiliu hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT jialinteng hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT junnaye hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT huishi hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT chengdeyang hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism AT xiaobingcheng hydroxychloroquineimprovesobesityassociatedinsulinresistanceandhepaticsteatosisbyregulatinglipidmetabolism |
_version_ |
1725154832740777984 |